If cannabis is to be accepted by the medical community (meaning patients, doctors, researchers, pharma companies, regulators…), there is much to be done in terms of testing the plant, standardizing dosages, and cataloging its effects. After decades of prohibition, scientists are racing to determine and document the potential benefits of cannabis in the treatment of a wide range of conditions, including but not limited to seizures, PTSD, chronic pain, inflammatory disorders, and sleep problems. It’s a sprawling, wild industry with many inherent barriers to standardization, classification, and quantification.
One company, RYAH MedTech, has developed a suite of smart devices backed by powerful data analytics tools, designed to help researchers, clinical trial organizations, doctors, patients, growers, and dispensaries get the data they need to maximize their effectiveness. Data is the fundamental pillar of science and technology, and RYAH is able to capture seed-to-consumption information of different plant-based medicinal formulations through its Internet of Things (IoT) product ecosystem. As a result, RYAH can understand the roles of formulations and dosing in treatment, using quantitative data and qualitative feedback.
RYAH just announced the closing of its reverse takeover transaction, followed quickly by the announcement that the newly-combined public company will be trading on the Canadian Securities Exchange under the symbol ‘RYAH’ as of May 4th. Let’s take a look at what the company offers.
RYAH’s Products – Smart and Connected